Permutations of time and place in tuberculosis

The Lancet Infectious Diseases

Volumn 15, Issue 11, 2015, Pages 1357-1360

  Elkington, Paul T ^a   Friedland, Jon S ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TRANSMISSION; BCG VACCINATION; CASE FINDING; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LIFE CYCLE; LUNG ALVEOLUS MACROPHAGE; LUNG CAVITATION; LUNG GRANULOMA; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PANDEMIC; PRE-EXPOSURE PROPHYLAXIS; PRIMARY INFECTION; PRIMARY TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SECONDARY INFECTION; TUBERCULOSIS; BIOLOGICAL MODEL; IMMUNOLOGY; LUNG; PATHOLOGY;

HUMANS; LUNG; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84945438758     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00135-8     Document Type: Review

References (49)

1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C Tuberculosis. Lancet 2003, 362:887-899.
2. Yoder MA, Lamichhane G, Bishai WR Cavitary pulmonary tuberculosis: the Holey Grail of disease transmission. Current Sci 2004, 86:74-81.
3. Ghon A The primary lung focus of tuberculosis in children 1916, xxiv. J & A Churchill, London, 172.
4. Canti RG Primary pulmonary tuberculosis in children. Q J Med 1919, 13:71-81.
5. Blacklock JW The primary lung focus of tuberculosis in children. Proc R Soc Med 1932, 25:725-733.
6. Murray JF Bill Dock and the location of pulmonary tuberculosis: how bed rest might have helped consumption. Am J Respir Crit Care Med 2003, 168:1029-1033.
7. Paulson T Epidemiology: a mortal foe. Nature 2013, 502:S2-S3.
8. Russell DG, Barry CE, Flynn JL Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
9. Cambier CJ, Falkow S, Ramakrishnan L Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 2014, 159:1497-1509.
10. Orme IM, Robinson RT, Cooper AM The balance between protective and pathogenic immune responses in the TB-infected lung. Nat Immunol 2014, 16:57-63.
11. Kahneman D Thinking, fast and slow 2013, Farrar, Straus and Giroux, New York. 1st edn.
12. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004, 8:392-402.
13. Aktogu S, Yorgancioglu A, Cirak K, Kose T, Dereli SM Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. Eur Respir J 1996, 9:2031-2035.
14. Dock W Apical localization of phthisis; its significance in treatment by prolonged rest in bed. Am Rev Tuberc 1946, 53:297-305.
15. Hunter RL, Actor JK, Hwang SA, Karev V, Jagannath C Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in the development of cavities. Ann Clin Lab Sci 2014, 44:365-387.
16. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
17. Kwan CK, Ernst JD HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011, 24:351-376.
18. Hunter RL, Jagannath C, Actor JK Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb) 2007, 87:267-278.
19. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 2009, 174:2190-2201.
20. Goodwin RA, Des Prez RM Apical localization of pulmonary tuberculosis, chronic pulmonary histoplasmosis, and progressive massive fibrosis of the lung. Chest 1983, 83:801-805.
21. Elkington PT, D'Armiento JM, Friedland JS Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med 2011, 3:71ps6.
22. Elkington P, Shiomi T, Breen R, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 2011, 121:1827-1833.
23. Al Shammari B, Shiomi T, Tezera L, et al. The extracellular matrix regulates granuloma necrosis in tuberculosis. J Infect Dis 2015, 212:463-473.
24. Fields GB Interstitial collagen catabolism. J Biol Chem 2013, 288:8785-8793.
25. Swift J, Ivanovska IL, Buxboim A, et al. Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 2013, 341:1240104.
26. Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137:122-128.
27. Kubler A, Luna B, Larsson C, et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J Pathol 2015, 235:431-444.
28. Young D Animal models of tuberculosis. Eur J Immunol 2009, 39:2011-2014.
29. Schwander S, Dheda K Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011, 183:696-707.
30. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
31. Sweeney KA, Dao DN, Goldberg MF, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17:1261-1268.
32. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
33. Kaufmann SH, Hussey G, Lambert PH New vaccines for tuberculosis. Lancet 2010, 375:2110-2119.
34. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
35. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003, 71:2192-2198.
36. Balbin M, Fueyo A, Knauper V, et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001, 276:10253-10262.
37. Nedeltchev GG, Raghunand TR, Jassal MS, Lun S, Cheng QJ, Bishai WR Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun 2009, 77:598-603.
38. Yamamura Y, Ogawa Y, Maeda H Prevention of tuberculous cavity formation by desensitization with tuberculin-active peptide. Am Rev Respir Dis 1974, 109:594-601.
39. Kaufmann SH, Schaible UE 100th anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus. Trends Microbiol 2005, 13:469-475.
40. Comstock GW, Livesay VT, Woolpert SF The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974, 99:131-138.
41. Walker NF, Clark SO, Oni T, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med 2012, 185:989-997.
42. Elkington PT Tuberculosis: time for a new perspective?. J Infect 2013, 66:299-302.
43. Yaesoubi R, Cohen T Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics. Proc Natl Acad Sci USA 2013, 110:9457-9462.
44. Walter ND, Painter J, Parker M, et al. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med 2014, 189:88-95.
45. Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013, 13:362-372.
46. Seddon J, Kasprowicz V, Walker NF, et al. Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis. J Infect Dis 2013, 208:1571-1579.
47. Lawn SD Diagnosis of pulmonary tuberculosis. Curr Opin Pulm Med 2013, 19:280-288.
48. McNerney R, Daley P Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011, 9:204-213.
49. Hawn TR, Matheson AI, Maley SN, Vandal O Host-directed therapeutics for tuberculosis: can we harness the host?. Microbiol Mol Biol Rev 2013, 77:608-627.